Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Tight liquidity NBB
Cash and receivables cover 56 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
FRAPEJA PHARMA from Gent, company number BE0562774303, closed financial year 2025 with a result of € -37,162 after tax. For that financial year FRAPEJA PHARMA recorded a gross margin of € 53,628 and equity of € 135,972. Compared with financial year 2024, the result moved from € -3,517 to € -37,162. The company made a loss. The company holds a healthy buffer. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on June 5, 2026.
€ 135,972
▼ 21% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -37,162
▼ 957 % more loss than in 2024
Profit after tax over the fiscal year.
€ 6,780
▲ 6% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -514,028.
People and assets in 2025
0
Average over the fiscal year, from the social balance sheet.
€ 15,804
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 270,248
▼ 14% vs 2024
€ 45,583 is repaid this year. At this pace the long-term loan is gone in ≈ 6 years.
€ 214,485
▲ 60% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 1,818
▼ 62% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 189,631 | € 195,066 | € 81,631 | € 53,628 | ▼ 34% |
| Profit after taxes | € 98,142 | € 111,137 | € -3,517 | € -37,162 | ▼ € 33,645 |
| Equity | € 65,514 | € 176,651 | € 173,134 | € 135,972 | ▼ 21% |
| Total debts | € 829,232 | € 656,804 | € 629,051 | € 636,974 | ▲ 1% |
| Cash | € 15,963 | € 12,432 | € 6,425 | € 6,780 | ▲ 6% |
| Retained profit | € -584,486 | € -473,349 | € -476,866 | € -514,028 | ▼ € 37,162 |
| Bank debt | € 410,394 | € 357,010 | € 314,110 | € 270,248 | ▼ 14% |
| Balance sheet total | € 894,746 | € 833,455 | € 802,185 | € 772,946 | ▼ 4% |
Key figures of FRAPEJA PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to FRAPEJA PHARMA?
What happened at FRAPEJA PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 37,162. Source: NBB ↗
- Frapeja Invest BV became a director. NBB
- New establishment in Gent. KBO
- New establishment in Gent. KBO
- Start of the company according to the CBE. KBO
In short
From € 98,142 profit in 2022 to € 37,162 loss in 2025.
Best year ever: 2023, with € 111,137 profit.
A new publication or filing at FRAPEJA PHARMA? We notify you, reason included.
Follow FRAPEJA PHARMADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of Farcilia comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
FRAPEJA PHARMABehind FRAPEJA PHARMA is Frapeja Invest BV. The shares are held by Farcilia (50%).
Directors
According to the 2025 annual accounts
Director · represented by Steven Van Gansbeke
Also active at: PHARTRIM, Apotheek Muide
since 2024
Shareholders
50%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Meulesteedsesteenweg 7
9000 Gent
Ottergemsesteenweg-Zuid 808 box C006
9000 Gent
Active since 18 June 2019
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 3 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0562.774.303
- VAT number
- BE 0562.774.303
- Registered office
- Meulesteedsesteenweg 7, 9000 Gent
- Names & denominations
- FRAPEJA PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 18 September 2014
- Peppol
- Active · Active since 12 Aug 2025
- Activities · NACE
Detailhandel in farmaceutische producten